Hypertrophic Cardiomyopathy Therapeutics Market Analysis | 2021-2026

Market Insights

The hypertrophic cardiomyopathy therapeutics market was estimated at USD 1.3 billion in 2020 and is likely to grow at a CAGR of 2.4% during 2021-2026 to reach USD 1.49 billion in 2026.

Want to know more about the market scope? Register Here

Market Dynamics

Introduction

Hypertrophic cardiomyopathy is referred to as a disorder where the heart muscle becomes abnormally thick or hypertrophied. The thickened heart muscle then causes the heart to be ineffective in pumping blood. This disease usually goes undiagnosed as many people with the disease have no or lesser symptoms. The therapies to treat HCM include beta-blockade and verapamil alone or in combination.

Covid-19 Impact

The COVID-19 pandemic has negatively influenced the hypertrophic cardiomyopathy therapeutics industry. The healthcare industry is currently facing major challenges as it is unable to provide proper medical facilities to meet the ever-growing coronavirus patient pool.

Market Drivers

The major factors driving the growth of the hypertrophic cardiomyopathy therapeutics market are:

• A growing number of the population is witnessing heart disease, which is among the key causes of death across the globe.
• Rising awareness programs regarding several organizations about the lethality of the disease.

Moreover, increasing R&D activities of the drugs used for the treatment propels the industry growth during the review period.

Want to have a closer look at this market report? Click Here.

Key Players

Key players operating in the global market are:

• Astra Zeneca Plc (UK)
• ADVANZ PHARMA Corp (Concordia Healthcare Corp) (UK)
• Bayer AG (Germany)
• Gilead Sciences, Inc (US)
• Merck & Co., Inc (US)
• Mylan N.V. (US)
• Novartis AG (Switzerland)
• Pfizer, Inc (US)
• Sanofi S.A. (France)
• Teva Pharmaceutical Industries Ltd (Israel)

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Segment’s Analysis

By Drug Class Type

Based on drug class, the hypertrophic cardiomyopathy therapeutics market has been classified into antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, calcium channel blockers, and others. The calcium channel blockers segment accounted for the largest market in 2020. Calcium channel blockers are commonly used as antihypertensive drugs that act by reducing the amount of calcium that goes into the cardiac muscle cells and causes them to relax, which bolsters segment growth.

Regional Insights

By region, the North American market accounted for the highest share in 2020 and is expected to grow at a robust CAGR during the review period. The Hypertrophic Cardiomyopathy (HCM) Therapeutics market growth is mainly attributed to the surge in healthcare expenditure, technologically advanced healthcare infrastructure, and well-established medical companies. Moreover, growing healthcare expenditure rising prevalence of congestive heart failure, and sedentary lifestyles of individuals, thus augmenting the market growth.

The Asia Pacific hypertrophic cardiomyopathy therapeutics market is expected to grow at a healthy CAGR during the review period due to increasing healthcare expenditure in emerging countries and rising STDs, and increasing awareness of heart diseases in emerging countries of China and India, further bolsters the regional market growth.

Know the high-growth countries in this report. Register Here

Research Methodology

• This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s hypertrophic cardiomyopathy therapeutics market realities and future market possibilities for the forecast period of 2021 to 2026.
• The report segments and analyzes the market in the most detailed manner to provide a panoramic view of the market.
• The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.
• This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
• More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.
• We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market. The following are the key features of the report:

• Market structure: Overview, industry life cycle analysis, supply chain analysis.
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
• Market trend and forecast analysis.
• Market segment trend and forecast.
• Competitive landscape and dynamics: Market share, Service portfolio, New Product Launches, etc.
• COVID-19 impact and its recovery curve
• Attractive market segments and associated growth opportunities.
• Emerging trends.
• Strategic growth opportunities for the existing and new players.
• Key success factors.

Market Segmentation

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The hypertrophic cardiomyopathy therapeutics market is segmented into the following categories.

By Drug Class Type

• Antiarrhythmic Agents
• Anticoagulants
• Beta Adrenergic Blocking Agents
• Calcium Channel Blockers
• Others

By End-User Type

• Cervical Cancer
• Anal Cancer
• Penile Cancer
• Oropharyngeal Cancer
• Genital Warts
• Others

By Region

• North America (Country Analysis: the USA, Canada, and Mexico)
• Europe (Country Analysis: Germany, France, the UK, Russia, Spain, and Rest of Europe)
• Asia-Pacific (Country Analysis: China, Japan, India, South Korea, and Rest of Asia-Pacific)
• Rest of the World (Sub-Region Analysis: Latin America, the Middle East, and Others)

Click Here, to learn the market segmentation details.

Report Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@Stratviewresearch.com.